Achillion

Biopharma throws grease on the deal wheels
EP Vantage
Wed, 07/21/21 - 10:52 am
M&A
Alexion
Achillion
Eli Lilly
Prevail Therapeutics
Alexion Ends Rare Kidney Disease Program Following Poor Data
BioSpace
Fri, 07/31/20 - 11:06 pm
Alexion Pharmaceuticals
Achillion
M&A
kidney disease
Alexion dumps ex-Achillion C3G program after seeing phase 2 data
Fierce Biotech
Thu, 07/30/20 - 11:01 am
Alexion
Achillion
M&A
clinical trials
After Alexion buyout, ex-Achillion nephrology lead jumps ship to Gemini Therapeutics
Fierce Biotech
Fri, 05/8/20 - 10:21 am
Alexion Pharma
Achillion
nephrology
Gemini Therapeutics
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms
Xconomy
Wed, 10/16/19 - 12:48 pm
Alexion Pharmaceuticals
Achillion
M&A
PNH
danicopan
Soliris
After rocky hep C path, Achillion finds surer footing with FDA breakthrough status
Endpoints
Wed, 09/25/19 - 11:32 pm
Achillion
FDA
paroxysmal nocturnal hemoglobinuria
Soliris
PNH
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
Sat, 05/11/19 - 12:31 pm
biotech
Achillion
Sesen Bio
The Medicines Company
Amgen
Daiichi Sankyo
earnings
Achillion Meets Enrollment Target in Kidney Disease Studies
Yahoo/Zacks.com
Thu, 04/4/19 - 12:11 pm
Achillion
ACH-4471
kidney disease
clinical trials
Why Achillion Pharmaceuticals, Inc. Stock Spiked Monday
Motley Fool
Mon, 02/26/18 - 07:25 pm
Achillion
Europe
kidney disease
ACH-4471
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
Endpoints
Mon, 09/11/17 - 09:40 am
JNJ
Achillion
hepatitis C
odalasvir
ACH-3102
J&J advances through PhII with a promising hep C triple and 100% cure rate
Endpoints
Fri, 09/9/16 - 10:21 am
JNJ
hepatitis C
clinical trials
odalasvir
AL-335
Olysio
Achillion
8 Major FDA Decisions and Trial Results to Watch for in September
24/7 Wall St
Sat, 09/3/16 - 12:17 pm
FDA
Achillion
odalasvir
AL-335
simeprevir
Amarin
Vascepa
Array Biopharma
binimetinib
Mast Therapeutics
vepoloxamer
Novavax
Threshold Pharmaceuticals
tarloxotinib
3 Biotechs Expecting Market-Moving Trial Results Soon
Motley Fool
Mon, 06/6/16 - 11:07 am
biotech
Ophthotech
Achillion
Kite Pharma
odalasvir
JNJ
Fovista
KTE-C19
Achillion's Pipeline Strengthens, With Near-Term Potential Catalysts
Seeking Alpha
Wed, 05/25/16 - 11:31 am
Achillion
ACH-4471
JNJ
hepatitis C
Buying These 2 Drug Developers Would Make a Lot of Sense for Johnson & Johnson
Motley Fool
Thu, 03/31/16 - 11:05 am
JNJ
drug development
M&A
Geron
Achillion
3 Small-Cap Biotech Stocks With Big News Coming in 2016
Motley Fool
Sat, 12/12/15 - 02:05 pm
biotech
Ophthotech
Fovista
andexanet alfa
Portola Pharmaceuticals
ACH-3102
Achillion
4 Key FDA Decisions Expected By Year End
24/7 Wall St
Sun, 11/29/15 - 12:43 pm
FDA
Achillion
hepatitis C
Biocryst
OPuS-2
BCX4161
Tetraphase Pharmaceuticals
Lucitanib
Clovis Oncology
Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?
Motley Fool
Tue, 09/29/15 - 09:04 am
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
AbbVie
Viekira Pak
Achillion
Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo
Bidness, ETC
Fri, 09/18/15 - 10:56 am
JNJ
Achillion
hepatitis C
Sovaldi
Gilead Sciences
ACH-3102
odalasvir
What Will Gilead Buy Next? 4 Possible Targets
Investors.com
Wed, 07/15/15 - 06:30 pm
Gilead Sciences
M&A
Incyte
Vertex Pharmaceuticals
Bristol-Myers Squibb
Achillion

Pages